What is KeraNetics?
KeraNetics, Inc. operates at the intersection of biotechnology and patient care, focusing on the development of advanced medical products for radiation dermatitis. The company's flagship offering, KeraStat Cream, represents a significant advancement in managing the side effects of radiotherapy, providing relief for patients suffering from skin irritation and soreness. Developed in collaboration with the Wake Forest Institute for Regenerative Medicine, the firm utilizes cutting-edge research to address critical gaps in supportive cancer care. By maintaining FDA-cleared status, KeraNetics serves a vital role for both healthcare providers and patients, ensuring that quality of life remains a priority during intensive cancer treatment protocols.
How much funding has KeraNetics raised?
KeraNetics has raised a total of $5.5M across 3 funding rounds:
Private Equity
$3.4M
Debt
$1.9M
Debt
$150K
Private Equity (2015): $3.4M, investors not publicly disclosed
Debt (2017): $1.9M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in KeraNetics
PPP
Public-Private Partnership
Undisclosed Investor
A private equity participant specializing in long-term capital deployment for healthcare and regenerative medicine ventures.
Undisclosed Investor
An institutional backer providing strategic debt financing to facilitate the commercial expansion of FDA-cleared medical products.
What's next for KeraNetics?
With the recent influx of capital, KeraNetics is well-positioned to accelerate its commercialization strategy and deepen its penetration into the radiotherapy support market. The company's roadmap likely involves expanding its distribution networks and potentially diversifying its product pipeline to address broader dermatological injuries. As the firm transitions from its foundational development phase into a more mature enterprise-level entity, the focus will remain on clinical efficacy and the integration of its regenerative technologies into standard oncology care pathways. This strategic growth phase is expected to enhance the company's competitive advantage in the specialized medical device sector.
See full KeraNetics company page
